Entera Bio Ltd. (ENTX)Healthcare | Biotechnology | Jerusalem, Israel | NasdaqCM
1.62 USD
-0.02
(-1.220%) ⇩
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:29 a.m. EDT
The long-term outlook remains deeply concerning due to a severe multi-year structural decline; the stock has lost over 73% of its value since 2018, with five out of seven years showing negative returns, including a catastrophic 76% drop in 2022. Despite recent news of FDA backing and pipeline showcases, the fundamental reality is stark: the company is burning cash with negative free cash flow, negative operating cash flow, and negative returns on both assets and equity. The balance sheet, while currently liquid, cannot sustain these burn rates indefinitely without further dilution. The short-term rating is neutral because the recent price action shows some recovery, but the overwhelming put buying in the options chain suggests traders are still fleeing the falling knife. The massive discrepancy between the $9.00 analyst target and the current price is likely a reflection of a binary event (like a successful trial readout) rather than a belief in sustainable business quality, making this a high-risk speculative play rather than an investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.114025 |
| AutoARIMA | 0.128235 |
| AutoETS | 0.133956 |
| AutoTheta | 0.140016 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 9.17 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.003 |
| Excess Kurtosis | 0.50 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.192 |
| Market Cap | 79,850,176 |
| Forward P/E | -2.95 |
| Beta | 1.43 |
| Website | https://enterabio.com |
As of July 11, 2026, 4:29 a.m. EDT: Speculators are positioning defensively with heavy put volume at the $2.00 strike for the nearest expiration, while call activity is sparse and concentrated at lower strikes ($2.50). The implied volatility skew shows significantly higher pricing for downside protection compared to upside potential, indicating a market consensus focused on avoiding further losses rather than anticipating a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.12765956 |
| Address1 | Kiryat Hadassah Minrav Building |
| Address2 | 5th Floor |
| All Time High | 10.16 |
| All Time Low | 0.472 |
| Ask | 1.67 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 264,190 |
| Average Daily Volume3 Month | 1,055,401 |
| Average Volume | 1,055,401 |
| Average Volume10Days | 264,190 |
| Beta | 1.433 |
| Bid | 1.77 |
| Bid Size | 1 |
| Book Value | 0.229 |
| City | Jerusalem |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.62 |
| Current Ratio | 7.927 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.66 |
| Day Low | 1.59 |
| Debt To Equity | 4.192 |
| Display Name | Entera Bio |
| Earnings Timestamp End | 1,754,913,600 |
| Earnings Timestamp Start | 1,754,564,340 |
| Ebitda | -12,476,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.096 |
| Enterprise Value | 76,056,024 |
| Eps Forward | -0.55 |
| Eps Trailing Twelve Months | -0.26 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.3477 |
| Fifty Day Average Change | 0.2723 |
| Fifty Day Average Change Percent | 0.20204794 |
| Fifty Two Week Change Percent | -12.765956 |
| Fifty Two Week High | 3.22 |
| Fifty Two Week High Change | -1.6 |
| Fifty Two Week High Change Percent | -0.49689442 |
| Fifty Two Week Low | 0.91 |
| Fifty Two Week Low Change | 0.71 |
| Fifty Two Week Low Change Percent | 0.78021973 |
| Fifty Two Week Range | 0.91 - 3.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,530,192,600,000 |
| Float Shares | 40,374,608 |
| Forward Eps | -0.55 |
| Forward P E | -2.9454546 |
| Free Cashflow | -4,841,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 20 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | 0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.231 |
| Held Percent Institutions | 0.1598 |
| Implied Shares Outstanding | 49,290,234 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel. |
| Long Name | Entera Bio Ltd. |
| Market | us_market |
| Market Cap | 79,850,176 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_106997294 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -12,377,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 80,835,983 |
| Number Of Analyst Opinions | 1 |
| Open | 1.63 |
| Operating Cashflow | -9,056,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 972 2 532 7151 |
| Previous Close | 1.64 |
| Price Hint | 4 |
| Price To Book | 7.074236 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 2.625 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.01999998 |
| Regular Market Change Percent | -1.219511 |
| Regular Market Day High | 1.66 |
| Regular Market Day Low | 1.59 |
| Regular Market Day Range | 1.59 - 1.66 |
| Regular Market Open | 1.63 |
| Regular Market Previous Close | 1.64 |
| Regular Market Price | 1.62 |
| Regular Market Time | 1,784,059,201 |
| Regular Market Volume | 151,570 |
| Return On Assets | -0.45009 |
| Return On Equity | -0.82332003 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 49,290,234 |
| Shares Percent Shares Out | 0.0067000003 |
| Shares Short | 332,658 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 177,670 |
| Short Name | Entera Bio Ltd. |
| Short Percent Of Float | 0.0078 |
| Short Ratio | 0.12 |
| Source Interval | 15 |
| Symbol | ENTX |
| Target High Price | 9.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 9.0 |
| Target Median Price | 9.0 |
| Total Cash | 4,137,000 |
| Total Cash Per Share | 0.084 |
| Total Debt | 448,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.26 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.679605 |
| Two Hundred Day Average Change | -0.059605002 |
| Two Hundred Day Average Change Percent | -0.03548751 |
| Type Disp | Equity |
| Volume | 151,570 |
| Website | https://enterabio.com |
| Zip | 9,112,002 |